What is the current stock price of Interpace Biosciences, Inc. (IDXG)?

As of the latest market data, Interpace Biosciences, Inc. (IDXG) is trading at $1.80. The stock has seen a loss of -1.10% today.

Does Interpace Biosciences, Inc. (IDXG) pay a dividend?

Based on current data, Interpace Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Interpace Biosciences, Inc.?

The current market capitalization of Interpace Biosciences, Inc. (IDXG) is approximately unavailable.

IDXG

Interpace Biosciences, Inc.·Healthcare

1.80

1.099%(−0.02)

Close Price

1.84

2.222%(+0.04)

Pre-Market

Last Updated: — ET

52W L: $0.7052W H: $2.40

IDXG NEWS

globenewswire.com

May 12

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

globenewswire.com

May 12

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

defenseworld.net

Apr 24

Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)

Institutional and Insider Ownership 7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 5.5% of Interpace Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money

defenseworld.net

Apr 23

Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG)

Earnings and Valuation This table compares Dynatronics and Interpace Biosciences"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dynatronics $33.60 million 0.00 -$2.70 million ($1.35) -0.01 Interpace Biosciences $38.73 million 0.23 $24.58 million ($0.02) -99.88 Interpace Biosciences has higher revenue and earnings than Dynatronics. Interpace

defenseworld.net

Apr 21

Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

Interpace Biosciences, Inc. (OTCMKTS:IDXG - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $1.41 and traded as high as $2.10. Interpace Biosciences shares last traded at $2.0460, with a volume of 4,515 shares trading hands. Interpace Biosciences

globenewswire.com

Mar 30

Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results

PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business and financial update.

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

111

IPO Date

1998-05-20

Beta

0.61

Websitewww.interpace.com↗